Web11 jun. 2024 · The Company believes this data supports its ongoing multi-center, open label, dose-escalation and dose expansion Phase I clinical trial (STELLAR-001), evaluating the … Web1 okt. 2024 · IPH5401, a fully human anti-C5aR1 antibody, inhibits the C5a mediated effects on MDSC and neutrophils. Preclinical data suggest that the combined blockade of …
A Phase I Study of the Anti-C5aR, IPH5401, in Combination
WebDescription. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally ... Web1 sep. 2024 · This is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, antitumor activity of IPH5401 (anti C5aR) in combination with Durvalumab (MEDI4736) in Adult Subjects with selected advanced solid tumors. chinese food in ankeny iowa
Preliminary results of STELLAR-001, a dose escalation
WebWe are proud to contribute to the scientific advancements on innate immunity and NK cells. Since our founding in 1999, our researchers have been published in several high impact … WebDive Brief: French biotech Innate Pharma has snagged worldwide exclusive development and commercialization rights to a Novo Nordisk anti-C5aR antibody. The antibody, now known as IPH5401, had previously been in Phase 1 trials for its use in patients with rheumatoid arthritis. Innate will switch the focus for the antibody to immuno-oncology. WebIph5401 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating iph5401, 1 is phase 1 (1 open). BRAF D594E, BRAF D594G, and BRAF D594H are the most frequent biomarker inclusion criteria for iph5401 clinical trials. grand junction co police